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Pre- or postoperative chemotherapy in patients with colorectal cancer 
with synchronous, resectable liver metastases?
Rafał Stec
At the moment, there is no clear scientific data on the use of preoperative chemotherapy in patients with colorectal, 
synchronous, resectable liver metastases. Below arguments are presented against the use of preoperative chemothe-
rapy in the above clinical situation, based on an analysis of three issues: the toxicity of preoperative chemotherapy 
and associated perioperative complications, the efficacy of pre- and postoperative chemotherapy, doubts related to 
the use of preoperative chemotherapy. To summarise, most scientific data is against preoperative chemotherapy as 
it causes significant adverse effects (hepatotoxicity and consequent postoperative complications) without a signi-
ficant improvement in survival rates. Therefore, postoperative chemotherapy in this group of patients seems to be 
the more optimal treatment.
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At the moment, there is no clear scientific data for the 
use of preoperative chemotherapy in patients with colo-
rectal, synchronous, resectable liver metastases. Below 
arguments are presented against the use of preoperative 
chemotherapy in the above clinical situation based on an 
analysis of three issues: 
a) the toxicity of preoperative chemotherapy and associa-
ted perioperative complications, 
b) the efficacy of pre- and postoperative chemotherapy,
c) doubts related to the use of preoperative chemotherapy.
The toxicity of preoperative chemotherapy and related 
perioperative complications are important elements that 
should directly influence therapeutic decisions.
A retrospective study published in 2006 evaluated the 
hepatotoxicity of preoperative chemotherapy in patients 
at the University of Texas MD Anderson Cancer Center, 
who underwent liver resection due to metastatic lesions 
of colorectal cancer between 1992 and 2005. The analysis 
covered a total of 406 patients; 248 received preoperative 
chemotherapy (204 were originally resectable and 44 were 
originally non-resectable), while the comparative group 
consisted of 158 patients who underwent surgery without 
prior chemotherapy. Treatment according to schemes based 
on irinotecan was associated with an increase in hepatic 
toxicity in the form of steatohepatitis, 8,4% in the entire 
population; 20.2% vs 4.4% in the group without chemo-
therapy; p = 0.001; OR = 5.4; 95% CI 2.2–13.5), while the 
use of oxaliplatin with sinusoidal dilation (damage to liver 
venous sinus, 5.4% in the entire population; 18,9% vs 1.9% 
in the group without chemotherapy; p = 0.001; OR = 8.3; 
95% CI 2.9–23.6), abnormalities in the liver venous sinuses. 
Patients with steatohepatitis (mainly those treated according 
to irinotecan chemotherapy schemes) revealed a higher risk 
of 90-day postoperative mortality compared to patients wi-
thout steatohepatitis (14.7% vs 1.6%, respectively): p = 0.001; 
OR = 10.5; 95% CI, 2.0 to 36.4) [1].
In the systematic review (Lehamn et al. 2012), to which 
a total of 81 publications were classified (20 concerning 
the regression of metastatic lesions, 14 related to neoadju-
vant chemotherapy in patients with potentially resectable 
metastases, 17 with hepatotoxicity of preoperative chemo-
therapy and 30 with complications after liver resection due 
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to metastatic lesions), on the one hand, the lack of benefits 
in terms of survival improvement from preoperative che-
motherapy in patients with resectable metastatic lesions 
was demonstrated, and on the other, a significant increase 
in hepatotoxicity of chemotherapy and the related risk of 
postoperative complications [2].
Another systematic review and meta-analysis (Robinson 
et al. 2012), comprising a total of 28 clinical trials, confirmed 
specific hepatic toxicity of oxaliplatin-based chemotherapy 
in the form of damage to venous liver sinuses of grade II 
or higher (RR = 4.36; 95% CI 1.36–13.97) and irinotecan-
-based chemotherapy as steatohepatitis (RR = 3.45; 95% 
CI 1.12–13.97). In their conclusions, the authors stressed 
a significant increase in the risk of liver damage associated 
with preoperative chemotherapy, which may have an ad-
verse effect on hepatic functional reserve in patients with 
metastases of colorectal cancer to the liver that were remo-
ved through a resection of a significant volume of liver [3].
The above observations were confirmed in the retro-
spective analysis (Martis et al. 2016), to which finally 140 
patients were classified (70 received neoadjuvant chemo-
therapy based on irinotecan, oxaliplatin and 5-fluorouracil 
with or without a biological agent and 70 without prior 
chemotherapy), who underwent resection of metastatic 
lesions from the liver. Multivariate analysis showed that 
venous sinus damage following chemotherapy was an in-
dependent cause of liver function disorders (p = 0.02) and 
liver-specific postoperative complications (p = 0.016) [4].
Another study indicating significant hepatic toxicity of 
preoperative chemotherapy is a systematic review (Zhao et 
al. 2017) in which 788 patients were included. The authors of 
the multivariate analysis confirmed that severe dilatation of 
venous sinuses (oxaliplatin treatment) was associated with 
an increase in the main prevalence (Clavien-Dindo classifica-
tion of surgical complications, grades III-V [grade III — neces-
sary surgical, radiological or endoscopic intervention, grade 
IV — life-threatening complications, grade V — patient’s 
death]; OR = 1.73, 95% CI 1.02 to 2.95; p =  0.043), while 
steatohepatitis (treatment with irinotecan) correlated with 
an increase in postoperative complications such as ascites, 
postoperative liver failure, biliary “leakage”, intra-abdominal 
abscesses, abdominal haemorrhaging, postoperative mor-
tality (OR = 2.08, 95% 1.18 to 3.66; p = 0.012) [5].
In addition to toxicity, the second most important pa-
rameter of the planned therapy is the efficacy of pre- and 
postoperative chemotherapy, which should be assessed in 
the light of objective scientific evidence.
In the summary analysis of two randomised clinical 
trials (Mitry et al. 2008), in which 278 patients were inclu-
ded (138 in the group treated with adjuvant chemothera-
py after surgical treatment and 140 in the group treated 
with exclusive surgical treatment), the impact of the use of 
adjuvant chemotherapy after the resection of metastatic 
lesions from the liver on survival rates was assessed. In the 
analysis of the whole population, patients with metastases 
≤ 1 year in the group undergoing combined treatment ac-
counted for 43.5%, and in the group with exclusive surgery 
for 42.9%. The median time of progression-free survival (PFS) 
was 27.9 months in the group with combined treatment 
and 18.8 months in the group with only surgical treatment 
(HR = 1.32; 95% CI, 1.00–1.76; p = 0.058), while the median 
time of overall survival was 62.2 months compared to 47.3 
months respectively (HR = 1.32; 95% CI, 0.95–1.82; p = 0.095). 
Adjuvant chemotherapy has proven to be an independent 
lengthening factor for both PFS and OS, but with threshold 
significance. It is worth emphasising that the use of subopti-
mal chemotherapy containing 5-fluorouracil and folinic acid, 
but without oxaliplatin, is recommended. The addition of 
a third drug (oxaliplatin) might be associated with statistical 
significance [6].
An important publication (Gallagher et al. 2009), despi-
te its retrospective nature (a retrospective analysis of 111 
patients from the Memorial Sloan-Kettering Cancer Center 
[MSKCC] surgical register, whose data were collected pro-
spectively), is an assessment of the efficacy (response to tre-
atment) of neoadjuvant chemotherapy in OS in patients with 
colorectal cancer with synchronous, resectable metastases to 
the liver. A multidimensional OS model for liver resection con-
tained the following independent, negative factors: presence 
of positive surgical margins (HR = 2.41, 95% CI, 1.06–5.47; 
p = 0.035), presence of metastases in initially removed lymph 
nodes (HR = 2.43, 95% CI, 1.08–5.51); p = 0.033) and post-
-resection level of CEA marker ≥ 5 ng/dL (HR = 2.51, 95% 
CI, 1.32–4.78; p = 0.005); however no correlation was found 
between OS and the response to neoadjuvant chemotherapy. 
The exclusion of this dependence may suggest the lack of 
benefits of its application before the surgical procedure and 
indicates the use of chemotherapy after surgical treatment [7].
Similar conclusions were reached by Nanji et al. (2013) 
in the retrospective analysis, in which 320 patients with 
resectable liver metastases were included (39.1% were pa-
tients with synchronous metastases). Multivariate analysis 
identified 4 factors that independently influence the OS: size 
of metastases > 6 cm (HR = 2.2, 95% CI, 1.3–3.5; p = 0.002), 
the presence of metastases in initially removed lymph no-
des, trait N1 (HR = 2.0, 95% CI, 1.0–3.8; p = 0.045) and trait 
N2 (HR = 2.4, 95% CI, 1.2–4.9); p = 0.017), the presence of 
synchronous metastases (HR = 2.1, 95% CI, 1.3–3.5; p = 0.003) 
and chemotherapy after resection of metastatic lesions from 
the liver (HR = 0.42, 95% CI, 0.23–0.75; p = 0.004) [8].
Another published retrospective analysis (Faron M et 
al. 2014) presented the results of chemotherapy according 
to the FOLFOX program in the period preceding surge-
ry or after the metastatic lesions resection from the liver. 
The analysis covered 179 patients, of whom over half were 
patients with the presence of synchronous metastases to 
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the liver (58%). In multivariate analysis, postoperative che-
motherapy according to the FOLFOX programme proved 
to be an independent predictive factor for prolongation of 
both overall survival time (OS — overall survival; HR = 0.55 
[95% CI, 0.35–0.87] p = 0.01] and disease free survival (DFS); 
HR = 0.54 [95% CI, 0.36–0.82] p = 0.0017). The use of preope-
rative chemotherapy according to the FOLFOX program did 
not result in a significant increase in vital parameters such 
as OS and DFS; OS (HR = 0.96 [95% CI, 0.57–1.6] p = 0.87) 
and DFS (HR = 1.05 [0.66–1.66] p = 0.83), respectively [9].
In a large, multi-centre, retrospective analysis of patients 
from the European Register (Bonney et al. 2015), whose data 
were collected prospectively, the efficacy of neoadjuvant 
chemotherapy in patients with colorectal cancer with syn-
chronous resectable liver metastases was evaluated. Out of 
over eleven thousand patients, 1301 patients were analysed, 
divided into two groups: one receiving preoperative chemo-
therapy (693 patients) and one in which the patients were 
operated on without previous chemotherapy (608 patients). 
In multivariate analysis, the independent factors affecting 
OS deterioration were: trait N(+) > 1, the number of metasta-
ses above 3, the serum concentration of CEA above 5 ng/ml 
and the absence of adjuvant chemotherapy, while for DFS: 
trait N(+) > 1, serum concentration of CEA above 5 ng/ml and 
the absence of adjuvant chemotherapy. Summarising the 
obtained results, the authors have drawn a clear conclusion 
that preoperative chemotherapy does not have a positive 
effect on survival parameters in this group of patients [10].
The benefit of adjuvant chemotherapy was obtained 
by a retrospective analysis of patients (227 patients) from 
one of the centres (Nishioka et al. 2017), whose were also 
collected in a prospective manner. The patients were divided 
into 3 groups: with the presence of synchronous metastases 
of colorectal cancer to the liver, with “early” metachronous 
metastases to the liver (≤ 1 year) and patients with “late” 
metachronous metastases to the liver (> 1 year). The 5-year 
time of relapse free survival (RFS) in patients with or without 
adjuvant chemotherapy was 32.8 / 11.2% in patients with 
synchronous metastases, S-CLM (p = 0.002), 43.7 / 15.2%, re-
spectively, in patients with early metachronous metastases 
that occurred ≤ 1 year, EM-CLM (p = 0.002), 44.1 / 29.6% in 
patients with metachronous metastases that occurred > 1 
year, LM-CLM (p = 0.163). In turn, 5-year overall survival (OS) 
rates in patients with or without adjuvant chemotherapy 
was 77.9 / 45.5% in patients with synchronous metastases, 
S-CLM (p = 0.021), 81.5 / 39.5%, respectively, in patients 
with metachronous metastases that appeared ≤ 1 year, EM-
-CLM (p = 0.015), 76.1 / 65.4% patients with metachronous 
metastases that appeared > 1 year, LM-CLM (p = 0.411). 
The presented data show an improvement in the survival 
parameters of patients with synchronous and early meta-
chronous metastases of colorectal cancer to the liver, but 
after chemotherapy adjuvant to the surgical procedure [11].
Improvement of survival parameters following adjuvant 
chemotherapy after preoperative chemotherapy and resec-
tion of mainly synchronous metastatic lesions from the liver 
(the majority of patients) was also observed in another retro-
spective analysis (Wang et al. 2017). The group of patients in 
whom postoperative treatment was applied, compared to 
the group of patients who were only followed up, obtained 
a significantly longer time to failure of treatment, as well as a 
longer overall survival time — median values, 10.2 months 
vs 3.3 months (p = 0.002) and 40.7 months vs 28.1 months 
(p = 0.005), respectively. These results confirm the value of 
postoperative chemotherapy as the leading systemic treat-
ment method in patients after the resection of metastatic 
lesions from the liver [12].
In connection with the planning of chemotherapy treat-
ment in patients with colorectal cancer, a number of doubts 
arise which cannot be ignored when planning treatment, 
especially as they may significantly affect the prognosis of 
patients. These are: 
 — delay in surgical treatment due to chemotherapy, which 
may result in the impossibility of technical removal of 
metastases after systemic treatment due to liver pro-
gression of metastatic lesions,
 — primary chemoresistance and associated extrahepatic 
progression, excluding the resection of metastatic le-
sions from the liver,
 — toxicity after chemotherapy, which makes it impossible 
to undergo surgery (especially the “aggravation” of si-
gnificant coexisting diseases, “patient inoperable” due 
to general reasons),
 — total regression of lesions in the liver after chemothe-
rapy (also lesions not visible in preoperative imaging), 
making it impossible to identify their location and the 
excision of scars by the surgeon.
 Summarising, at present there is no clear scientific evi-
dence for the use of preoperative chemotherapy in patients 
with colorectal cancer with synchronous metastases to the 
liver, while postoperative chemotherapy seems to be more 
optimal in this group of patients.
Response
The effectiveness of neoadjuvant chemotherapy was 
summarised (Nigri et al. 2015) in a systematic review (meta-
-analysis could not be performed due to potential statistical 
errors caused by a variety of chemotherapy regimens used 
in pre- or postoperative treatment) in which the effec-
tiveness of the therapy was compared in two groups of 
patients: those treated exclusively surgically with or without 
adjuvant chemotherapy (1785 patients) and those treated 
with chemotherapy before the surgery (1607 patients). 
The overall survival percentage in the group of patients 
treated surgically ranged from 20.7% to 56%, while in the 
group with neoadjuvant chemotherapy — from 38.9% to 
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74%, without statistically significant differences in 7 out 
of 8 subjects included in the study review. The systematic 
review did not confirm the use of neoadjuvant chemothe-
rapy in patients with colorectal cancer with resectable liver 
metastases [13].
ESMO recommendations (European Society for Me-
dical Oncology), as well as the NCCN (National Compre-
hensive Cancer Network) prefer, in the case of resectable 
synchronous metastases to the liver, especially in the case 
of favourable prognostic factors, to perform surgery first 
(primary tumour resection and metastasectomy performed 
simultaneously or in stages), and then to use adjuvant 
chemotherapy [14, 15].
There is still the problem of a potentially resectable 
cancer. In the era of modern, contemporary diagnostics: 
a PET-CT, liver MRI or modern ultrasound, one can strictly 
select patients with metastases of colorectal cancer to the 
liver and classify them into two groups: resectable (and 
adjuvant chemotherapy) and unresectable, but then we use 
induction, and not neoadjuvant chemotherapy.
With modern diagnostics, which is necessary before ma-
king a decision on metastasectomy, we can reduce the risk 
of “unnecessary” operations and correctly qualify patients 
to the appropriate groups. This is confirmed by the lack of 
clear criteria defining metastases as “potentially” resectable.
Most of the scientific data is against preoperative che-
motherapy, which has significant adverse effects (hepato-
toxicity and consequently postoperative complications) 
without significant improvement in survival rates.
A list of studies evaluating the efficiency of preopera-
tive chemotherapy against postoperative chemotherapy 
is given in Table I.
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